Search

Your search keyword '"Amelio D."' showing total 248 results
Start Over Author "Amelio D."
248 results on '"Amelio D."'

2. INFLUENCE OF THE 4D ROBUST PLANNING APPROACH ON THE COMPARISON BETWEEN PHOTON AND PROTON FOR THE TREATMENT OF STAGE III LUNG CANCER: A DOSIMETRIC AND RADIOBIOLOGICAL STUDY

Author

Widesott, L., primary, Landoni, V., additional, Dionisi, F., additional, Siniscalchi, B., additional, Nardangeli, A., additional, Fracchiolla, F., additional, Turkaj, A., additional, Soriani, A., additional, Righetto, R., additional, Goanta, L., additional, Farace, P., additional, Petrongari, M.G., additional, Trianni, A., additional, Amelio, D., additional, Lorentini, S., additional, Cianchetti, M., additional, and Sanguineti, G., additional

Published
2023
Full Text
View/download PDF

3. Clinical Outcomes and Dosimetric Predictive Factors in Patients Undergoing Reirradiation for Recurrent Meningiomas

Author

Desideri, I., primary, Scartoni, D., additional, Morelli, I., additional, Banini, M., additional, Visani, L., additional, Greto, D., additional, Detti, B., additional, Perini, Z., additional, Zivelonghi, E., additional, Bulgarelli, G., additional, Pinzi, V., additional, Pierina, N., additional, Clerici, E., additional, Ascolese, A.M., additional, Anselmo, P., additional, Amelio, D., additional, Osti, M.F., additional, Minniti, G., additional, and Livi, L., additional

Published
2023
Full Text
View/download PDF

6. PD-0652 Re-irradiation of recurrent intracranial meningiomas: an Italian multicenter retrospective study

Author

Desideri, I., primary, Morelli, I., additional, Visani, L., additional, Greto, D., additional, Detti, B., additional, Perini, Z., additional, Zivelonghi, E., additional, Bulgarelli, G., additional, Pinzi, V., additional, Navarria, P., additional, Clerici, E., additional, Ascolese, A.M., additional, Anselmo, P., additional, Amelio, D., additional, Osti, M.F., additional, Minniti, G., additional, Livi, L., additional, and Scartoni, D., additional

Published
2023
Full Text
View/download PDF

13. Quercetin and its derivative Q2 modulate chromatin dynamics in adipogenesis and Q2 prevents obesity and metabolic disorders in rats

Author

Nettore IC (1), Rocca C (2), Mancino G (1), Albano L(3, Amelio D (2), Grande F(5), Puoci F(5), Pasqua T(2), Desiderio S(1), Mazza R(2), Terracciano D(3), Colao A(1), Bèguinot F(3, Russo GL(6), Dentice M(1), Macchia PE(1), Sinicropi MS(5), Angelone T(2, Ungaro P(4)., Nettore, I. C., Rocca, C., Mancino, G., Albano, L., Amelio, D., Grande, F., Puoci, F., Pasqua, T., Desiderio, S., Mazza, R., Terracciano, D., Colao, A., Beguinot, F., Russo, G. L., Dentice, M., Macchia, P. E., Sinicropi, M. S., Angelone, T., and Ungaro, P.

Subjects
Male, 0301 basic medicine, Cell Survival, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Biological Availability, Diet, High-Fat, Biochemistry, Chromatin remodeling, Epigenesis, Genetic, Histones, Mice, 03 medical and health sciences, Histone H3, 0302 clinical medicine, 3T3-L1 Cells, Adipocytes, Animals, Benzopyrans, Obesity, Rats, Wistar, Molecular Biology, Epigenomics, Adipogenesi, Adipogenesis, Nutrition and Dietetics, biology, Chemistry, Epigenetic, Polyphenols, Lipid Metabolism, Chromatin, Cell biology, PPAR gamma, 030104 developmental biology, Histone, 030220 oncology & carcinogenesis, CCAAT-Enhancer-Binding Proteins, Histone modifications, biology.protein, Demethylase, Quercetin, Anti-Obesity Agents, Histone modification, Chromatin immunoprecipitation
Abstract

Recently the attention of the scientific community has focused on the ability of polyphenols to counteract adverse epigenetic regulation involved in the development of complex conditions such as obesity. The aim of this study was to investigate the epigenetic mechanisms underlying the anti-adiposity effect of Quercetin (3,3′,4′,5,7-pentahydroxyflavone) and of one of its derivatives, Q2 in which the OH groups have been replaced by acetyl groups. In 3 T3-L1 preadipocytes, Quercetin and Q2 treatment induce chromatin remodeling and histone modifications at the 5′ regulatory region of the two main adipogenic genes, c/EBPα and PPARγ. Chromatin immunoprecipitation assays revealed a concomitant increase of histone H3 di-methylation at Lys9, a typical mark of repressed gene promoters, and a decrease of histone H3 di-methylation at Lys 4, a mark of active transcription. At the same time, both compounds inhibited histone demethylase LSD1 recruitment to the 5′ region of c/EBPα and PPARγ genes, a necessary step for adipogenesis. The final effect is a significant reduction in c/EBPα and PPARγ gene expression and attenuated adipogenesis. Q2 supplementation in rats reduced the gain in body weight and in white adipose tissue, as well as the increase in adipocyte size determined by high fat diet. Moreover, Q2 improved dyslipidemia, glucose tolerance and decreased the hepatic lipid accumulation by activating the expression of beta-oxidation related genes. Our data suggest that Q2, as well as Quercetin, has the potential to revert the unfavorable epigenomic profiles associated with obesity onset. This opens the possibility to use these compounds in targeted prevention strategies against obesity.

Published
2019
Full Text
View/download PDF

17. Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO)

Author

Navarria, P, Minniti, G, Clerici, E, Tomatis, S, Pinzi, V, Ciammella, P, Galaverni, M, Amelio, D, Scartoni, D, Scoccianti, S, Krengli, M, Masini, L, Draghini, L, Maranzano, E, Borzillo, V, Muto, P, Ferrarese, F, Fariselli, L, Livi, L, Pasqualetti, F, Fiorentino, A, Alongi, F, di Monale, M, Magrini, S, Scorsetti, M, Navarria P., Minniti G., Clerici E., Tomatis S., Pinzi V., Ciammella P., Galaverni M., Amelio D., Scartoni D., Scoccianti S., Krengli M., Masini L., Draghini L., Maranzano E., Borzillo V., Muto P., Ferrarese F., Fariselli L., Livi L., Pasqualetti F., Fiorentino A., Alongi F., di Monale M. B., Magrini S., Scorsetti M., Navarria, P, Minniti, G, Clerici, E, Tomatis, S, Pinzi, V, Ciammella, P, Galaverni, M, Amelio, D, Scartoni, D, Scoccianti, S, Krengli, M, Masini, L, Draghini, L, Maranzano, E, Borzillo, V, Muto, P, Ferrarese, F, Fariselli, L, Livi, L, Pasqualetti, F, Fiorentino, A, Alongi, F, di Monale, M, Magrini, S, Scorsetti, M, Navarria P., Minniti G., Clerici E., Tomatis S., Pinzi V., Ciammella P., Galaverni M., Amelio D., Scartoni D., Scoccianti S., Krengli M., Masini L., Draghini L., Maranzano E., Borzillo V., Muto P., Ferrarese F., Fariselli L., Livi L., Pasqualetti F., Fiorentino A., Alongi F., di Monale M. B., Magrini S., and Scorsetti M.

Abstract

Introduction: The prognosis of glioma is dismal, and almost all patients relapsed. At recurrence time, several treatment options are considered, but to date there is no a standard of care. The Neurooncology Study Group of the Italian Association of Radiation Oncology (AIRO) collected clinical data regarding a large series of recurrent glioma patients who underwent re-irradiation (re-RT) in Italy. Methods: Data regarding 300 recurrent glioma patients treated from May 2002 to November 2017, were analyzed. All patients underwent re-RT. Surgical resection, followed by re-RT with concomitant and adjuvant chemotherapy was performed. Clinical outcome was evaluated by neurological examination and brain MRI performed, 1 month after radiation therapy and then every 3 months. Results: Re-irradiation was performed at a median interval time (IT) of 16 months from the first RT. Surgical resection before re-RT was performed in 19% of patients, concomitant temozolomide (TMZ) in 16.3%, and maintenance chemotherapy in 29%. Total doses ranged from 9 Gy to 52.5 Gy, with a median biological effective dose of 43 Gy. The median, 1, 2 year OS were 9.7 months, 41% and 17.7%. Low grade glioma histology (p ≪ 0.01), IT > 12 months (p = 0.001), KPS > 70 (p = 0.004), younger age (p = 0.001), high total doses delivered (p = 0.04), and combined treatment performed (p = 0.0008) were recorded as conditioning survival. Conclusion: our data underline re-RT as a safe and feasible treatment with limited rate of toxicity, and a combined ones as a better option for selected patients. The identification of a BED threshold able to obtain a greater benefit on OS, can help in designing future prospective studies.

Published
2019

27. AngII-dependent morpho-functional remodelling of the zebrafish heart

Author

Filice M, Barca A, Amelio D, Verri T, Cerra MC, Imbrogno S., Filice, M, Barca, A, Amelio, D, Verri, T, Cerra, Mc, and Imbrogno, S.

Abstract

Programme and Abstracts of the 68th National Congress of the Italian Physiological Society (Società Italiana di Fisiologia)

Published
2018

30. Dosimetric and NTCP advantages of robust proton therapy over robust VMAT for Stage III NSCLC in the immunotherapy era.

Author

Dionisi, F., Landoni, V., Widesott, L., Nardangeli, A., Fracchiolla, F., Siniscalchi, B., Soriani, A., Turkaj, A., Righetto, R., Amelio, D., Farace, P., Goanta, L., Trianni, A., Lorentini, S., Cianchetti, M., and Sanguineti, G.

Abstract

• Robust proton vs x-ray planning on free-breathing (FB) STAGE III NSCLC was tested. • A reduction of NTCP risk of pulmonary and cardiac toxicity was scored with protons. • A reduction in the dose to the immune system was observed with protons. • Robust optimization is an interesting and novel solution also for x-ray therapy. • Robust FB proton therapy could be an effective option for selected STAGE III NSCLC. To assess the robustness and to define the dosimetric and NTCP advantages of pencil-beam-scanning proton therapy (PBSPT) compared with VMAT for unresectable Stage III non-small lung cancer (NSCLC) in the immunotherapy era. 10 patients were re-planned with VMAT and PBSPT using: 1) ITV-based robust optimization with 0.5 cm setup uncertainties and (for PBSPT) 3.5 % range uncertainties on free-breathing CT 2) CTV-based RO including all 4DCTs anatomies. Target coverage (TC), organs at risk dose and TC robustness (TCR), set at V95%, were compared. The NTCP risk for radiation pneumonitis (RP), 24-month mortality (24MM), G2 + acute esophageal toxicity (ET), the dose to the immune system (EDIC) and the left anterior descending (LAD) coronary artery V15 < 10 % were registered. Wilcoxon test was used. Both PBSPT methods improved TC and TCR (p < 0.01). The mean lung dose and lung V20 were lower with PBSPT (p < 0.01). Median mean heart dose reduction with PBSPT was 8 Gy (p < 0.001). PT lowered median LAD V15 (p = 0.004). ΔNTCP > 5 % with PBSPT was observed for two patients for RP and for five patients for 24 MM. ΔNTCP for ≥ G2 ET was not in favor of PBSPT for all patients. PBSPT halved median EDIC (4.9/5.1 Gy for ITV/CTV-based VMAT vs 2.3 Gy for both ITV/CTV-based PBSPT, p < 0.01). PBSPT is a robust approach with significant dosimetric and NTCP advantages over VMAT; the EDIC reduction could allow for a better integration with immunotherapy. A clinical benefit for a subset of NSCLC patients is expected. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. EP-1837 A new hybrid approach to allow robust Monte Carlo-based multi-field optimization in proton therapy

Author

Tommasino, F., primary, Widesott, L., additional, Fracchiolla, F., additional, Lorentini, S., additional, Righetto, R., additional, Algranati, C., additional, Scifoni, E., additional, Dionisi, F., additional, Scartoni, D., additional, Amelio, D., additional, Cianchetti, M., additional, Schwarz, M., additional, Amichetti, M., additional, and Farace, P., additional

Published
2019
Full Text
View/download PDF

37. Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologists

Author

Furlan, C, Arcangeli, S, Avanzo, M, Mirri, MA, Munoz, F, Giudici, S, Perrone, A, Amelio, D, Tornio, L, Draghini, L, DELI, ANIKO' MARIA, Pavanato, G, Giuliano, FM, Pontoriero, A, Ciammella, P, Navarria, P, Lannalfi, A, Buglione, M, Guida, C, Cammelli, S, Lorio, V, Cardinali, M, Genovesi, D, Barsacchi, L, Balducci, M, Bagnoli, R, Berti, F, Montesi, G, Pasqualetti, F, Bonome, P, Santoni, R, Doino, D, Schirru, P, Pinzi, V, Borzillo, V, Ferrarese, F, Ferro, M, De Cicco, L, Krengli, M, Scoccianti, S, Donato, V, PINZI, VALENTINA, Furlan, Carlo, Arcangeli, Stefano, Avanzo, Michele, Mirri, Maria A, Munoz, Fernando, Giudici, Stefania, Perrone, Antonio, Amelio, Dante, Tomio, Luigi, Draghini, Loredana, Deli, Aniko M, Pavanato, Giovanni, Giugliano, Francesca M, Pontoriero, Antonio, Ciammella, Patrizia, Navarria, Pierina, Iannalfi, Alberto, Buglione, Michela, Guida, Cesare, Cammelli, Silvia, Iorio, Vincenzo, Cardinali, Massimo, Genovesi, Domenico, Barsacchi, Lucia, Balducci, Mario, Bagnoli, Rita, Berti, Franco, Montesi, Giampaolo, Pasqualetti, Francesco, Bonome, Paolo, Santoni, Riccardo, Doino, Daniela, Schirru, Patrizia, Pinzi, Valentina, Borzillo, Valentina, Ferrarese, Fabio, Ferro, Marica, De Cicco, Luigi, Krengli, Marco, Scoccianti, Silvia, Donato, Vittorio, Furlan, C, Arcangeli, S, Avanzo, M, Mirri, M, Munoz, F, Giudici, S, Perrone, A, Amelio, D, Tornio, L, Draghini, L, Deli, A, Pavanato, G, Giuliano, F, Pontoriero, A, Ciammella, P, Navarria, P, Lannalfi, A, Buglione, M, Guida, C, Cammelli, S, Lorio, V, Cardinali, M, Genovesi, D, Barsacchi, L, Balducci, M, Bagnoli, R, Berti, F, Montesi, G, Pasqualetti, F, Bonome, P, Santoni, R, Doino, D, Schirru, P, Pinzi, V, Borzillo, V, Ferrarese, F, Ferro, M, De Cicco, L, Krengli, M, Scoccianti, S, and Donato, V

Subjects
Oncology, Male, Cancer Research, medicine.medical_specialty, Adolescent, medicine.medical_treatment, gliomas (HGG), Radiosurgery, 030218 nuclear medicine & medical imaging, Re-Irradiation, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Glioma, Surveys and Questionnaires, Reirradiation, gliomas (HGG), Medicine, Humans, dose, glioblastoma, glioma, IMRT, radiosurgery, reirradiation, IMRT, Reirradiation, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Salvage Therapy, RECURRENT HIGH GRADE GLIOMA, business.industry, Dose, Glioblastoma, Radiation Oncologists, General Medicine, medicine.disease, Combined Modality Therapy, SURVEY, Current management, Italy, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business
Abstract

Purpose: To assess the contribution of Italian radiation oncologists in the current management of recurrent high-grade gliomas (HGG), focusing on a reirradiation (reRT) approach. Methods: In 2015, the Reirradiation and the Central Nervous System Study Groups on behalf of the Italian Association of Radiation Oncology (AIRO) proposed a survey. All Italian radiation oncologists were individually invited to complete an online questionnaire regarding their clinical management of recurrent HGG, focusing on a reRT approach. Results: A total of 37 of 210 questionnaires were returned (18% of all centers): 16 (43%) from nonacademic hospitals, 14 (38%) from academic hospitals, 5 (13%) from private institutions, and 2 (6%) from hadron therapy centers. The majority of responding centers (59%) treated ≤5 cases per year. Performance status at the time of recurrence, along with a target diameter Conclusions: Although there were wide variations in the clinical practice of reRT across the 37 centers, the core activities were reasonably consistent. These findings provide a basis for encouraging a national collaborative study to develop, implement, and monitor the use of reRT in this challenging clinical setting.

Published
2017

42. P01.069 Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter retrospective study by the Brain-Study-Group of the Radiation Oncology Italian Association (AIRO)

Author

Navarria, P, primary, Minniti, G, additional, Pinzi, V, additional, Draghini, L, additional, Borzillo, V, additional, Ciammella, P, additional, Scoccianti, S, additional, Amelio, D, additional, Krengli, M, additional, and Buglione di Monale, M, additional

Published
2018
Full Text
View/download PDF

50. Practice patterns of image guided particle therapy in Europe: a 2016 survey of the European Particle Therapy Network (EPTN)

Author

Bolsi, A., Peroni, M., Amelio, D., Dasu, A., Stock, M., Toma-Dasu, I., Witt Nyström, P., Hoffmann, A. L., Bolsi, A., Peroni, M., Amelio, D., Dasu, A., Stock, M., Toma-Dasu, I., Witt Nyström, P., and Hoffmann, A. L.

Abstract

Background and Purpose: Image guidance is critical in achieving accurate and precise radiation delivery in particle therapy, even more than in photon therapy. However, equipment, quality assurance procedures and clinical workflows for image-guided particle therapy (IGPT) may vary substantially between centres due to a lack of standardization. A survey was conducted to evaluate the current practice of IGPT in European particle therapy centres. Material and Methods: In 2016, a questionnaire was distributed among 19 particle therapy centres in 12 European countries. The questionnaire consisted of 30 open and 37 closed questions related to image guidance in the general clinical workflow, for moving targets, current research activities and future perspectives of IGPT. Results: All centres completed the questionnaire. The IGPT methods used by the 10 treating centres varied substantially. The 9 non-treating centres were in the process to introduce IGPT. Most centres have developed their own IGPT strategies, being tightly connected to their specific technical implementation and dose delivery methods. Conclusions: Insight into the current clinical practice of IGPT in European particle therapy centres was obtained. A variety in IGPT practices and procedures was confirmed, which underlines the need for harmonisation of practice parameters and consensus guidelines.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results